Evergreen Telehealth on the July 2026 PCAC Peptide Review

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to review seven peptides for potential inclusion on the federal list of bulk drug substances that determines what licensed pharmacies may legally compound. All seven have now been decided. The committee recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion. It voted against recommending Emideltide, also known as DSIP.

These are recommendations only. None of these substances are legal to compound today. The FDA must still decide whether to pursue formal rulemaking, which includes publishing a proposed rule, an approximately 60 to 90 day public comment period, and a final rule that typically takes effect 30 days after publication. How long FDA itself takes to complete its internal drafting and review is not predictable.

Evergreen Telehealth is a LegitScript certified personalized medicine telehealth platform that partners with top 1% national PCAB and ASHP-accredited pharmacies. Patients researching these peptides today are largely turning to unregulated online sellers with no prescription requirement, no purity testing, and no practitioner oversight.

Dr. Casey Greene, PharmD, FMCP, Director of Consultative Services at Evergreen Telehealth, said: "Patients deserve peptides with expert physician guidance and licensed pharmacy quality-controls, not unregulated online gray market sources that put them at great risk."

Evergreen is monitoring the FDA's rulemaking process and will be ready to offer a licensed compounding pathway for these peptides if and when that process is complete. Until then, we are focused on giving patients and clinicians accurate, current information about where things stand.